PRF Technologies (PRFX) Return on Capital Employed (2021 - 2024)
PRF Technologies' (PRFX) quarterly Return on Capital Employed came in at 2729.86% in Q2 2024, up 285100.0% YoY from N/an in Q3 2023, and down 19.82% on a QoQ basis from 3404.55% in Q1 2024.
PRF Technologies (PRFX) Return on Capital Employed (2021 - 2024) Analysis & Trends
PRF Technologies (PRFX) has 4 years of Return on Capital Employed data on file, last reported at 2729.86% in Q2 2024.
- Quarterly Return on Capital Employed rose 285100.0% year-over-year to 2729.86% in Q2 2024, while the trailing twelve-month figure through Jun 2024 was 2729.86% (up 285100.0% YoY) and the FY2025 annual result came in at 88.0%, up 9773200.0% from the prior year.
- Return on Capital Employed fell to 2729.86% in Q2 2024, from 3404.55% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 3404.55% in Q1 2024 to a low of 192.72% in Q4 2023.
- A 4-year average of 378.4% and a median of 40.97% in 2022 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2023 — Return on Capital Employed sank 12192 bps — and 2024, when it jumped 349979 bps.
- Tracing PRFX's Return on Capital Employed over 4 years: stood at 38.04% in 2021, then sank by 86 bps to 70.8% in 2022, then sank by 172 bps to 192.72% in 2023, then surged by 1516 bps to 2729.86% in 2024.
- The last three Return on Capital Employed figures came in at 2729.86% (Q2 2024), 3404.55% (Q1 2024), and 192.72% (Q4 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.42 Bn | 43.46 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.71 Bn | 40.06 Bn | 2.15 Bn | 6.60% |
| 3 | Zoetis | 32.56 Bn | 30.88 Bn | 1.05 Bn | 17.16% |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.84 Bn | 5.10 Bn | 6.07% |
| 5 | United Therapeutics | 22.08 Bn | 19.41 Bn | 683.80 Mn | 22.04% |
| 6 | Viatris | 18.92 Bn | 18.03 Bn | 1.46 Bn | -0.29% |
| 7 | Neurocrine Biosciences | 15.48 Bn | 15.09 Bn | 935.80 Mn | 18.67% |
| 8 | Elanco Animal Health | 11.99 Bn | 11.46 Bn | 798.00 Mn | 5.52% |
| 9 | Dr Reddys Laboratories | 10.15 Bn | 9.99 Bn | - | - |
| 10 | PRF Technologies | 654,452.72 | -3.49 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 2,729.86% |
| Mar 31, 2024 | 3,404.55% |
| Dec 31, 2023 | -192.72% |
| Sep 30, 2023 | -109.05% |
| Jun 30, 2023 | -121.14% |
| Mar 31, 2023 | -95.25% |
| Dec 31, 2022 | -70.80% |
| Sep 30, 2022 | -51.69% |
| Jun 30, 2022 | -43.11% |
| Mar 31, 2022 | -38.82% |
| Dec 31, 2021 | -38.04% |
| Sep 30, 2021 | -31.64% |
| Jun 30, 2021 | -25.47% |
| Mar 31, 2021 | -19.00% |